– Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) dosing, as characterized across multiple non-human primate (NHP) species –

– Compared head-to-head with other capsids engineered for CNS-IV delivery, Dyno bCap 1 performs significantly better overall in delivery to the CNS, liver detargeting, and production efficiency –

– The Dyno bCap 1 product and other proprietary capsids for CNS-IV delivery are available for immediate licensing to partners developing optimized gene therapies –

WATERTOWN, Mass., May 19, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that can expand the potential of genetic medicine, today announced the launch of its Dyno bCap 1™ capsid product, a breakthrough CNS-targeted AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. The Dyno bCap 1 vector provides dramatically improved CNS delivery and liver detargeting compared to leading natural capsids and stronger all-around characteristics relative to other engineered CNS-IV capsids.

“Safe and effective gene delivery to the brain is a primary factor limiting the treatment of CNS diseases with gene therapy today. We believe effective delivery to all cells throughout the brain will unlock the potential to treat patients affected by a variety of genetic diseases, including amyotrophic lateral sclerosis, Angelman syndrome, Parkinson’s disease and Alzheimer’s disease,” said Adrian Veres, M.D., Ph.D., CSO and Co-founder of Dyno. “We look forward to further exploring the transformative potential of Dyno bCap 1, as well as our growing line of capsid products, by partnering with leading developers of gene therapies.”

To create high-performing capsids, Dyno has pioneered the application of state-of-the-art methods in deep learning and generative artificial intelligence (AI) to protein sequence design, while also leveraging large, internally collected in vivo datasets that provide high-resolution insights into the many therapeutically relevant capsid delivery properties. By combining AI and high-throughput biology, Dyno’s platform is capable of more fully exploring the AAV capsid sequence space in search of capsids that are optimized across multiple dimensions, such as CNS targeting, liver detargeting, and production efficiency. As a result, the protein sequence for the Dyno bCap 1 product is highly novel, with a pattern of sequence changes that would not occur using methods most typically used for engineering AAV capsids, such as random mutation or insertion of short peptides in the capsid protein sequence. After AI-driven design of the capsid sequence, Dyno extensively characterized the in vivo delivery properties of Dyno bCap 1 across species in NHPs, the most relevant animal models for translation to humans.

Key Data on Dyno bCap 1 Technology

  • Relative to the commonly used AAV9 capsid, Dyno bCap1 exhibits 100-fold better pan-brain CNS transduction upon crossing of the blood-brain barrier and 10-fold better liver detargeting.
  • Dyno bCap1 improvements in transduction and targeting specificity are conserved across NHP species in both cynomolgus monkey (Macaca fascicularis) and African green monkey (Chlorocebus sabaeus), increasing confidence that the breakthrough CNS delivery capabilities of Dyno bCap 1 could be relevant for applications in human therapeutics.
  • Whereas naturally-derived capsids such as AAV9 transduce only a small fraction of brain cells in NHPs, with a low IV injected dose of 1e13vg/kg, payloads delivered by the Dyno bCap 1 capsid transduced between 4-14% of cells in the brain, and 5-20% of neurons across pan-brain regions and the spinal cord, potentially broadening the diseases which can be successfully treated with gene therapy.
  • Compared in library format head-to-head against an external engineered AAV capsid reported to have improved brain transduction relative to other CNS-IV capsids, Dyno bCap 1 demonstrated consistent brain transduction across animals, with comparable or improved transduction relative to the external capsid, and dramatically better production efficiency, demonstrating the transformative potential of Dyno bCap 1 for CNS-IV delivery.

Licensing Dyno bCap 1 Technology
Dyno Therapeutics is making Dyno bCap 1 technology and additional proprietary capsids with improved CNS delivery properties available immediately for licensing to gene therapy developers across academia and industry.

“Dyno’s business is partnership-centric: We partner with gene therapy developers, providing them with the very best capsids so that they can invest their efforts at the leading edge of genetic medicine,” said Dyno CEO and Co-founder, Eric Kelsic, Ph.D. “With the Dyno bCap1 launch, we are delivering on this promise for our partners, both existing and to come. We’re ready to build new partnering relationships in the CNS and beyond that will enable our industry to realize the potential of genetic medicines to help patients in need all around the world.”

About Dyno Therapeutics
Dyno Therapeutics is solving the in vivo gene delivery challenge while broadly partnering with gene therapy developers towards maximizing patient impact. Dyno’s platform combines AI with high-throughput experimentation to accelerate the design of AAV capsids with properties that significantly outperform current in vivo gene delivery vectors, with the goal of expanding the range of diseases treatable with genetic medicines. Dyno has partnered with leading gene therapy developers, including Astellas, Novartis, Roche, and Sarepta, and is broadly open to partnering across therapeutic areas. Dyno was founded in 2018 and is located in Watertown, Massachusetts. Visit www.dynotx.com for additional information.

Media Contact:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com

 

WATERTOWN, Mass., May 2, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of four research abstracts at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-20, 2023 in Los Angeles, Calif.

Among the results to be presented is a breakthrough in CNS delivery: Dyno’s AI-guided design and subsequent in vivo characterization of a novel AAV capsid that delivers genetic payloads to a significant and potentially therapeutically relevant fraction of neurons across the central nervous system (CNS), including deep brain structures, via IV administration in non-human primates.

Dyno Scientific Symposium
Title: “The Capsids You Need: AI-Guided Design and In Vivo Validation of AAV Capsids for Better Delivery to Muscle, Eye and CNS”
Date and Time: Friday, May 19 from 12:00-1:30 p.m. PT
Location: Petree Hall C

Dyno’s scientific symposium will describe the transformative properties of Dyno’s license-ready capsids across therapeutic areas, including a breakthrough in CNS delivery aided by generative AI.

Dyno is leveraging its platform to additionally design optimized capsids for muscle and eye delivery, towards significantly expanding the potential of genetic medicine.

Symposium speakers:
Eric Kelsic, Ph.D., CEO and Co-founder
Adrian Veres, Ph.D., CSO and Co-founder
Jamie Kwasknieski, Ph.D., Head of Platform
Yvette Leung, MBA, Head of Corporate Development

Research abstracts showcasing Dyno’s capsids:
Title: “Crossing the Non-Human Primate Blood Brain Barrier with Machine-Guided AAV Capsid Design”
Date and Time: Wednesday, May 17 at 12:00 p.m. PT
Poster/Abstract Number: 382

Title: “Optimizing Intravitreal Delivery to the Non-Human Primate Retina with Machine-Guided AAV Capsid Design”
Date and Time: Friday, May 19 at 12:00 p.m. PT
Poster/Abstract Number: 1284

Research abstracts featuring Dyno’s platform capabilities:
Title: “A Robust Machine Learning Algorithm for Improving AAV Capsid Performance”
Date and Time: Wednesday, May 17 at 12:00 p.m. PT
Poster/Abstract Number: 467

Title: “Automated Micro-TFF System Streamlines Purification and Operator Time in a Lean rAAV Manufacturing Operation”
Date and Time: Thursday, May 18 at 12:00 p.m. PT
Poster/Abstract Number: 887

Pre-meeting workshop and panel discussion:
Title: “Building the team that’s right for your startup”
Speaker: Eric Kelsic, PhD, CEO and Co-founder
Date and Time: Tuesday May 16, at 9:40 a.m PT, Concourse Hall 150 & 151
Session: The Magic Year – Founders tips for what to do in your last six months of academia and first six months in industry

About Dyno Therapeutics
Dyno Therapeutics is solving the in vivo gene delivery challenge while broadly partnering with gene therapy developers towards maximizing patient impact. Dyno’s platform combines artificial intelligence (AI) with high-throughput experimentation to accelerate the design of AAV capsids with properties that significantly outperform current in vivo gene delivery vectors, towards expanding the range of diseases treatable with genetic medicines. To date, Dyno has partnered with leading gene therapy developers, including Astellas, Novartis, Roche, Sarepta and is broadly open to partnering across therapeutic areas. Dyno was founded in 2018 and is located in Watertown, Massachusetts. Visit www.dynotx.com for additional information.

Media Contact:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbrigecommunications.com

Cloud native tools such as Kubernetes and Argo Workflows are improving productivity, accelerating innovation, and increasing operational efficiency. These tools reduce the burden of infrastructure management by enabling efficient and scalable management of complex computing tasks.

At Dyno Therapeutics, we have not only built a proprietary engine that leverages Kubernetes and Argo Workflows for our ML-guided design of AAV capsids, but we have also contributed to the open source community by developing and releasing Hera. Hera is a project that simplifies access to Argo Workflows, and we use it to design and execute complex workflows for vector design, biological data processing, and large scale data ingestion.

To learn more about how we’re leveraging the Cloud Native Computing Foundation ecosystem to scale our gene therapy research efforts at Dyno Therapeutics, check out our abstract and full talk below on “Scaling Gene Therapy Research with Argo Workflows and Hera” from ArgoCon 2023.

Abstract:
The use of cloud native tools such as Kubernetes and Argo Workflows is becoming increasingly popular across various domains, including gene therapy. These tools enable efficient and scalable management of complex computing tasks, allowing researchers and engineers to focus on their core product rather than infrastructure management. This has led to improved productivity, increased innovation, and increased operational efficiency. At Dyno Therapeutics, we use our proprietary engine called Dynet to generate and consume massive amounts of data to design and test vectors used for the delivery of gene therapy. Dyno leverages Kubernetes, Argo Workflows, and Hera to define, orchestrate, and execute complex workflows used for vector design, biological data processing, and large scale data ingestion. This talk will showcase novel applications of Argo Workflows and Kubernetes from a field as novel as gene therapy, and illustrate how tech products, such as Hera, from the Cloud Native Computing Foundation ecosystem help scale gene therapy research and engineering efforts.

Full talk: https://www.youtube.com/watch?v=h2TEw8kd1Ds&t=1s&ab_channel=CNCF%5BCloudNativeComputingFoundation%5D

BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, MD, PhD to Chief Scientific Officer!

Adam Poulin-Kerstien, JD, PhD, has extensive experience as a life sciences intellectual property and corporate attorney. While at Dyno, Adam defined Dyno’s IP strategy and supported Dyno’s broader legal needs as Head of Legal and member of the executive leadership team. Prior to joining Dyno, Adam worked for the Novartis Institutes for Biomedical Research where he led and coordinated IP support for Novartis’ respiratory disease and neuroscience research and development programs. Adam holds a BA in Chemistry from Amherst College, a PhD from Caltech, and a JD from UCLA School of Law.

Adrian Veres, MD, PhD is happiest combining experimental and computational biology to solve critical problems in developing the next generation of human medicines. As Dyno co-founder, his past roles include Head of People and Head of R&D. Adrian holds an A.B. in Physics and Chemistry from Harvard College, a PhD in Systems Biology from Harvard University and an MD with Honors from Harvard & MIT.

Adam and Adrian, we look forward to your leadership as we advance the frontiers of #genetherapy to transform patient lives with cutting-edge science!

About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit www.dynotx.com for additional information.

BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider, to the top 500 companies in the U.S.

America’s Best Startup Employers were selected by evaluating:

  • Employee satisfaction
  • Employer reputation
  • Company growth

Dyno is looking for dynamic and driven high-potential problem-solvers to support the optimization of AAV gene therapies to transform patient lives with cutting-edge science. Interested in becoming an AAViator and joining our team? Visit www.dynotx.com/careers to see all open positions.

 

About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit www.dynotx.com for additional information.

Discussing the Convergence of Biotechnology and Technology 

Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman Sachs Byte-ology Conference.

Dyno’s mission is to build the ideal capsid and solve the challenges of vivo gene delivery. Our data driven approach is a key enabler and differentiator. Dyno’s CapsidMap Platform is building the world’s most informative and diverse library of capsid measurements, and an algorithm that learns to efficiently explore sequence space in search of the best capsids for therapeutic delivery.

Tune in today at 11:00 ET to catch Eric Kelsic, CEO and co-founder: Click Here for Webcast

 

BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life Sciences Category at the ninth annual NEVY Awards by the New England Venture Capital Association (NEVCA). The awards recognize and celebrate the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem—the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. Presented again this year by Dell Technologies, winners were announced both live and in-person at House of Blues Boston and streamed virtually. 

“Dyno has a pioneering artificial intelligence (AI) led approach to solving gene therapy’s biggest challenge: the efficient, safe and precise gene delivery to target tissues,” said Eric Kelsic, PhD, chief executive officer and co-founder of Dyno Therapeutics. “We are honored to receive this recognition from NEVCA as Emerging Company of 2021 for the Life Sciences. Thanks to all AAViators for making this possible  through Collective Innovation: empowering a  diverse team of the best problem solvers to drive cutting-edge science towards improving patient health.” 

The NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them, and cover a broad spectrum of the region’s thriving industry clusters. The academies are broken out across Life Sciences, Healthcare, Climate Tech, MedTech and Technology.

“It was wonderful to celebrate our NEVYs award ceremony both in-person and virtually to honor the heroic companies and investors working to fortify the innovation in New England and beyond,” said NEVCA President, Jody Rose. “Those in our venture community are building a brighter and bolder future for all of us. Congratulations to the winners and nominees!”

Dyno Therapeutics joins an impressive list of outstanding companies from around New England, in categories across the innovation landscape.

The winners of the 2021 NEVY Awards in the Life Sciences category are:

  • Patient Impact Award: Moderna
  • Emerging Life Science Company of the Year: Dyno Therapeutics
  • Life Science Deal of the Year: Pandion Therapeutics

The winners of the 2021 NEVY Awards in the Healthcare category are:

  • Emerging Healthcare Company of the Year: FOLX Health
  • Powerhouse Healthcare Company of the Year: Reify Health
  • Liquidity Event of the Year: Iora Health

The winners of the 2021 NEVY Awards in the MedTech category are:

  • Emerging MedTech Company of the Year: PanTher Therapeutics
  • Powerhouse MedTech Company of the Year: Vicarious Surgical

The winners of the 2021 NEVY Awards in the Climate Tech category are:

  • Early Company of the Year: Sublime Systems
  • Powerhouse Climate Tech Company: Desktop Metal
  • Rocket Ship Company of the Year: Battery Resources

The winners of the 2021 NEVY Awards in the Technology category are:

  • Emerging Tech Company: Verve Motion
  • Hottest Tech Startup: Perch
  • Liquidity Event of the Year: Toast
  • Company of the Year: Whoop

The winner of the 2021 NEVY Awards Fund of the Year was: Bessemer Venture Partners

Alongside Presenting Sponsor Dell Technologies, the 2021 NEVY Awards were supported by Abbvie, Alexandria Real Estate Equities, Deloitte, IDA Ireland, Johnson & Johnson Innovation – JJDC, JP Morgan, Matter and V2 Communications.

About Dyno Therapeutics
Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit www.dynotx.com for additional information.


About CapsidMap™ for Designing Optimized AAV Gene Therapies
Dyno’s CapsidMap™ platform overcomes the limitations of gene therapies on the market and under development today by optimizing capsids, the cell-targeting protein shells of Adeno-Associated Virus (AAV) vectors. Current gene therapies primarily use a small number of naturally occurring capsids that are limited by delivery efficiency, pre-existing immunity, payload size, and manufacturing challenges. CapsidMap works in two stages, first by measuring capsid properties in high-throughput using next-generation DNA library synthesis and DNA sequencing. With these vast quantities of in vivo data, CapsidMap then generates improved capsid sequences by applying advanced search algorithms that leverage machine learning. Dyno’s comprehensive map of capsid sequence space and AI‑powered tools thereby accelerate the design of AAV gene therapies towards optimizing manufacturability and applicability for treating a broader range of diseases.

 

About the New England Venture Capital Association
The New England Venture Capital Association (NEVCA) works toward a collaborative, inclusive, and prosperous innovation ecosystem. Through unique program-building, critical policy work, innovative regional marketing and dynamic local events, the NEVCA invests in the entrepreneurial ecosystem on behalf of the VC community. From celebrations (the NEVY Awards) to content series (VC Briefings and Syndicate Sessions), workforce development programs (Hack.Diversity and the Bioscience & Investor Inclusion Group) to advocacy and legislation (noncompete and immigration reform), the NEVCA is at once a network, catalyst and resource for the innovation economy.

 

Dyno Therapeutics PR Contact:

Nisha Deo
Head of Communications
Tel: +1 857 242-0593

Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion

TOKYO and CAMBRIDGE, Mass.Dec. 2, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., “Dyno”) today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap™ platform. 

Dyno’s CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors – designed to optimize tissue targeting and immune-evading properties, in addition to improving packaging capacity and manufacturability. Unlike traditional approaches, CapsidMap is uniquely well-suited to simultaneously optimize capsids for delivery across multiple organs, with the goal of enabling more effective whole-body treatment for many diseases. 

With the establishment of the Astellas Gene Therapies Center of Excellence following the 2020 acquisition of Audentes Therapeutics Inc., Astellas is a leader in genetic medicines, working alongside its world-renowned partners to build a portfolio of potentially life-changing gene therapies. This research collaboration combines Dyno’s AI-powered AAV vector engineering capabilities with Astellas Gene Therapies global leadership in AAV-based pipeline assets. 

“Through our efforts in gene therapy and the Astellas Gene Therapies Center of Excellence, Astellas strives to identify, develop and deliver transformative gene-based therapies for patients with genetic diseases who currently have few or no effective treatment options. Our principal focus is on developing adeno-associated virus delivered therapies for the treatment of well-defined serious diseases,” said Naoki Okamura, Chief Strategy Officer and Chief Financial Officer, Chief Business Officer at Astellas. We are dedicated to delivering novel approaches and utilizing new technologies that can deliver transformational value for patients. 

“We are so happy to be partnering with Astellas, a world leader in developing gene therapies. Dyno and Astellas each bring unique strengths to this collaboration, together enabling more rapid creation of new therapies for patients with great unmet need,” said Dyno’s CEO and co-founder Eric D. Kelsic, Ph.D. “This partnership demonstrates the flexibility of Dyno’s platform to precisely design the delivery properties of gene therapy vectors towards multi-organ and disease-specific profiles, applying the scientific insights we are rapidly learning across all our partnered and internal vector engineering programs using CapsidMap.” 

Under the terms of the agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Astellas will be responsible for conducting preclinical, clinical and commercialization activities, including manufacturing, of gene therapy product candidates using the novel capsids. Dyno will receive an $18 million upfront payment and be eligible to receive additional payments during the research phase of the collaboration as well as clinical and sales milestone payments and royalties for any resulting products. The aggregate potential value of future milestone and royalty payments to Dyno exceeds $235 million per product and over $1.6 billion in total value. 

About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en. 

 About Astellas Gene Therapies
Astellas integrated its wholly owned subsidiary, Audentes Therapeutics, Inc. as of April 1, 2021 and established “Astellas Gene Therapies” within the organization as an Astellas Center of Excellence to develop genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and hope to also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina. 

 About Dyno Therapeutics
Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit www.dynotx.com for additional information.

About CapsidMap™ for Designing Optimized AAV Gene Therapies
Dyno’s CapsidMap™ platform overcomes the limitations of gene therapies on the market and under development today by optimizing capsids, the cell-targeting protein shells of Adeno-Associated Virus (AAV) vectors. Current gene therapies primarily use a small number of naturally occurring capsids that are limited by delivery efficiency, pre-existing immunity, payload size, and manufacturing challenges. CapsidMap works in two stages, first by measuring capsid properties in high-throughput using next-generation DNA library synthesis and DNA sequencing. With these vast quantities of in vivo data, CapsidMap then generates improved capsid sequences by applying advanced search algorithms that leverage machine learning. Dyno’s comprehensive map of capsid sequence space and AIpowered tools thereby accelerate the design of AAV gene therapies towards optimizing manufacturability and applicability for treating a broader range of diseases.

Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. 

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. 

 

### 

Contacts for inquiries or additional information: 

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201 

Dyno Therapeutics
Nisha Deo 
Head of Communications 
TEL: +1-857-242-0593  

 

Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid and solve the challenges of vivo gene delivery. We call ourselves AAViators and are engaged in Collective Innovation as we aim to maximize our impact on patients through the development of groundbreaking technologies.

AAViators assembled together in the summer of 2021

Our journey so far has been one of rigor and joy. We are so honored that the 2021 NEVY Awards Academy has nominated Dyno for the “Emerging Company of the Year” Award. Recently we’ve also been recognized with disruptive potential in the biopharma industry.

Our data driven approach is a key enabler and differentiator. With our CapsidMapTM Platform, Dyno is building the world’s most informative and diverse library of capsid measurements, and an algorithm that learns to efficiently explore sequence space in search of the best capsids for  therapeutic delivery. (Read more about how our platform is delivering the promise of gene therapy here)

Our other core differentiator is our focus on productive teamwork. Everytime a new AAViator accepts an offer to join the team we reiterate our foundation of trust, healthy conflict, commitment, accountability and attention to results. Onboarding at Dyno starts by reading Patrick Lencioni’s The Five Dysfunctions of a Team: A Leadership Fable, which enables discussions about these aspects of productive teamwork across the whole company. For example, this common language helps us explore the importance of being vulnerable and open about our weaknesses and mistakes, in order to build the trust required for teams to flourish. In recognizing the importance of trust we also realize how difficult it is to achieve.

We must therefore be open to give and receive feedback (both positive and negative) so that we improve trust at an individual, team, and organizational level. Similar best-practices apply for each concept all the way through attention to results (for more explanation, I highly recommend reading Lencioni’s book).

Scientific breakthroughs can emerge from the most uncanny places. We are structured in a way that makes it easier for anyone (regardless of hierarchy or discipline) at any level to propose a change to our platform, any of which could eventually lead to a scientific breakthrough.

Today we are over 60 full time AAViators. We continue to climb to meet the needs of every potential partner, and in the process hope to justify the accolades we have received. As we reach 150 strong we look forward to welcoming those with fresh ideas interested in catalyzing our Collective Innovation.

If you are looking for a hard working team-focused company where you can connect your creative ideas to real-world impact contact me directly or take a look at our Careers page!

Back to Top